|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Acute lymphocytic leukemia
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
|
11290608 |
2001 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
|
11290608 |
2001 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
|
11290608 |
2001 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
|
22504183 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
MicroRNAs in liver disease.
|
22504185 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
|
14604974 |
2004 |
|
MYELODYSPLASTIC SYNDROME
|
|
0.010 |
GeneticVariation
|
BEFREE |
One patient had FLT3/TKD mutation (D835Y) at both MDS and AML stages.
|
14737077 |
2004 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Our FLT3-Aurora kinase inhibitor, CCT137690, successfully inhibited growth of FLT3-ITD-D835Y cells in vitro and in vivo, suggesting that dual FLT3-Aurora inhibition may overcome selective FLT3 inhibitor resistance, in part due to inhibition of Aurora kinase, and may benefit patients with FLT3-mutated AML.
|
22354205 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
|
17047150 |
2007 |